Global U.S Bacterial Conjunctivitis Drugs Market - Size, Share, Analysis, Trends to 2024

Global U.s Bacterial Conjunctivitis Drugs Market - Future market

size in the U.S. is expected to grow (2024)

Persistence Market Research

Global U.s Bacterial Conjunctivitis Drugs

Market is expected to progress a market

worth of USD 439.8 million in 2024 Persistence Market Research

Persistence Market Research

1

Global U.s Bacterial Conjunctivitis Drugs Market - Future market

size in the U.S. is expected to grow (2024)

Persistence Market Research Released New Market Report “The U.S Market Study on

Bacterial Conjunctivitis Drugs -

fluoroquinolones to be the Largest Segment by

2024” the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million

in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR

of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the

outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into

three major categories: infective (viral and bacterial), allergic, and irritant (chemical).

Bacterial conjunctivitis is one of the most commonly observed eye problems across all age

groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata,

Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As

reported by Healio (specialty medical news and journal publisher), approximately 5 million

acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence

of bacterial conjunctivitis in the country demands effective medications, thereby driving the

growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the

increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in

the U.S. is likely to witness negative growth due to the patent expirations of major

blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few...